Ask him to discuss mitochondrial transplantation and the energy theory of aging.
5 Likes
-
What would be rapamycin schedule with iron-deficient low hemoglobin? Can rapamycin have a hormetic effect?
-
What does he think about 3mg per week dosage of rapamycin?
-
For starters, is it necessary to start with lower dosage and increase gradually (e.g. 3 to 5 mg)?
5 Likes
What data is there about Rapamycin blood levels. Is 24 hours post-pill a good sampling time. Does he have targets? If so, what are they?
5 Likes
Two questions: (1) Why does he personally cycle off rapa for 12 weeks (on 12 wks and off 12wks)? and (2) While he changed the dosing frequency for his canine study from the original 3x per week to now 1x per week (for participant feasibility reasons?), would he predict that the original 3x per week would be more effective in the real world for canine health and life span?
3 Likes
What’s his favorite colour.
3 Likes
Asking the real questions here. Anyway, wow guys that’s a lot of questions, we’ll see if I can keep him around for the full 8 hours hah.
FTR our conversation is on Wednesday, 16:00 UTC, so questions can come until then.
2 Likes
Ask him if he aspirates his TRT injections.
2 Likes
What’s your take on different ways of rapa administration, intra-muscular, intra-nasal…?
1 Like
I too would love to know the answer to this question.
1 Like
Hahaha… that’s old school.
Nobody aspirates TRT injections these days… or at least it is said to make no difference. I never have in 6 years… no issue.
3 Likes
3 Likes
Has Matt researched any AMPK activators? Any thoughts? They seem to have many benefits.
OS-01 - CAS 1261289-04-6 is mentioned & used by James LaValle in his longevity clinics here in Texas.
Ryan Smith has also mentioned their benefits.
1 Like
Thank you guys, I had a great conversation with Matt last night and I was able to ask many of your questions. More, we discussed the phenomena of this very forum as well. I’ll be back when it’s out.
8 Likes
Thanks for seeking some new ideas and information from Matt.
Very excited to hear your interview.
3 Likes
I would ask him a few things, maybe he has already been asked this:
- what if any biomarkers can be used for any positive or negative affects of rapa
- Given ASCVD is leading cause of death in USA (if I am not mistaken), any indication of impact on plaque
- I am guessing he is already on record about this final one, but given MTOR important for muscles, any negative impact on muscles by rapa
2 Likes
I hope you’ll post a link to the blog, podcast, or article you write up on the conversation!
5 Likes
Matt just did a podcast: A Scientific-Backed Discussion On Fighting Cognitive Decline.
Starting from the timestamp at 49 minutes, it covers supplements and medications. Really enjoyed all the information shared.
Podcast Summary: Optispan Brain Health Program
Hosts: Optispan Podcast
Guests: Eric Nelson (Human Sync) & Dr. Kevin White (Prime Health Associates)
Topic: A 3-Tier Protocol to Halt or Reverse Cognitive Decline
Key Takeaways
A new 12-month, 3-tier program is being developed to combat cognitive decline, targeting early-stage dementia, TBI survivors, and APOE4 carriers. The protocol layers interventions based on evidence, cost, and invasiveness.
3-Tier Intervention Framework
Tier 1: Foundational Lifestyle & Core Supplements
-
Lifestyle:
-
Anti-inflammatory diet (low processed foods, sugar).
-
Exercise: Cardio + resistance training.
-
Sleep optimization (wearables like WHOOP for HRV, resting HR).
-
Stress reduction (news fasts, cortisol/DHEA testing).
-
-
Core Supplements (High Confidence):
-
Omega-3 (EPA/DHA) – Cardiovascular + brain health.
-
Vitamin D3 – Optimal levels (50–80 ng/mL).
-
B-Complex + TMG – Methylation support (lowers homocysteine).
-
Magnesium (Mg3) – Crosses blood-brain barrier.
-
Creatine – 5–10g/day; neuroprotective.
-
Tier 2: Targeted Pharmaceuticals
-
Metabolic Health:
-
SGLT2 Inhibitors (e.g., empagliflozin) – GLP-1 agonists (e.g., semaglutide) for insulin resistance.
-
Metformin – Secondary to SGLT2s; debated for off-label use.
-
-
Neuroprotection:
-
Rapamycin – mTOR inhibition; early data shows brain volume preservation.
-
Low-Dose Naltrexone (LDN) – Anti-inflammatory; immune modulation.
-
PDE5 Inhibitors (e.g., Cialis) – Boosts cerebral blood flow.
-
Tier 3: Advanced/Experimental Therapies
-
Therapeutic Plasma Exchange (TPE) – Removes toxins (heavy metals, PFAS); expensive but promising.
-
Stem Cells/Exosomes – TBD; unregulated, limited evidence.
-
Peptides (e.g., Cerebrolysin, Dihexa) – Speculative; no robust data for dementia.
Diagnostics & Personalization
-
Genetics: APOE4, MTHFR screening.
-
Biomarkers:
-
Plasma Aβ42/40 ratio, NfL – Early plaque/axon damage.
-
Inflammation: hs-CRP, homocysteine, Lp-PLA2.
-
Metabolic: HbA1c, insulin, lipids.
-
-
Imaging:
-
MRI (hippocampal volume) – Tracks atrophy/regrowth.
-
Cognitive Testing: MoCA (limited), sensitive digital tools for SCI/MCI.
-
3 Likes
Yes definitely. I’m planning to release on Sept 18
3 Likes
Is there a way we could listen to your interview? Thanks!
1 Like
